Compare YOU & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YOU | AAPG |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.9B |
| IPO Year | 2021 | 2025 |
| Metric | YOU | AAPG |
|---|---|---|
| Price | $35.77 | $29.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $37.67 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 1.4M | 4.5K |
| Earning Date | 11-06-2025 | 11-19-2025 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ 88.46 | N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $866,298,000.00 | $54,524,554.00 |
| Revenue This Year | $17.43 | N/A |
| Revenue Next Year | $12.07 | $368.64 |
| P/E Ratio | $22.09 | ★ N/A |
| Revenue Growth | ★ 17.83 | N/A |
| 52 Week Low | $21.67 | $16.50 |
| 52 Week High | $39.00 | $48.45 |
| Indicator | YOU | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 39.37 |
| Support Level | $32.38 | $30.00 |
| Resistance Level | $36.92 | $32.96 |
| Average True Range (ATR) | 1.34 | 0.77 |
| MACD | -0.11 | -0.03 |
| Stochastic Oscillator | 72.93 | 33.43 |
Clear Secure Inc is an identity company making experiences safer and easier digitally and physically. It is involved in the creation of a frictionless travel experience while enhancing security. Its secure identity platform uses biometrics to automate the identity verification process through lanes in airports which helps to make the travel experience safe and easy.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.